ARTICLE | Regulation
Herculean task for DMD
How Duchenne UK’s HERCULES consortium hopes to improve access to DMD therapies
February 24, 2018 12:54 AM UTC
Driven by the delayed reimbursement decision for Europe’s only approved DMD therapy, the patient advocacy group Duchenne UK has brought together seven companies in the space to create a set of shared tools that should expedite HTA evaluations for all of their therapies.
Project HERCULES was launched in January with Pfizer Inc., PTC Therapeutics Inc., Roche, Sarepta Therapeutics Inc., Solid Biosciences Inc., Summit Therapeutics plc and Wave Life Sciences Ltd. Steering Committee members include CureDuchenne and Parent Project Muscular Dystrophy (PPMD)...
BCIQ Company Profiles